Mylan and Biocon launch Herceptin biosimilar in US

Mylan and Biocon have launched their Herceptin biosimilar Ogivri in the US, the second challenger to Roche’s breast and stomach cancer blockbuster.

FDA guidance finally opens door for insulin biosimilars

New draft guidance from the FDA has opened the door for the development of insulin biosimilars, potentially allowing for cheaper near-identical versions of these biologic drugs to be interc

NICE backs Lynparza across the board for BRCA+ovarian cancer

Drugs firms make massive discounts to get reimbursement in C...

Roche and Novartis are among the pharmaceuticals companies who have agreed to cut prices of some of their newest drugs by 61% on average to get them reimbursed in China, according to a repo

ICER says 'marginal' benefits for AbbVie's new RA drug

AbbVie’s Rinvoq rheumatoid arthritis drug is an important part of the company’s strategy to replace lost sales as its mega-blockbuster Humira finally succumbs to cheaper biosimilar competit

NICE backs Ibrance for breast cancer via Cancer Drugs Fund